Warangalone exhibits anti-malarial activity by inhibiting the growth of both chloroquine-sensitive (3D7) and chloroquine-resistant (K1) Plasmodium falciparum strains with IC50 values of 4.8 μg/mL and 3.7 μg/mL, respectively; it also inhibits cyclic AMP-dependent protein kinase catalytic subunit (cAK) with an IC50 of 3.5 μM; additionally, Warangalone suppresses HL-60 cell growth in a time-dependent manner and induces a reduction in cell viability, accompanied by a time-dependent increase in caspase-9 activity, suggesting potential anti-cancer applications.